Unicycive Therapeutics Inc (UNCY) - Total Liabilities
Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) has total liabilities worth $18.94 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Unicycive Therapeutics Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Unicycive Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Unicycive Therapeutics Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Unicycive Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Unicycive Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Catella AB (publ)
ST:CAT-B
|
Sweden | Skr2.18 Billion |
|
Arman Financial Services Limited
NSE:ARMANFIN
|
India | Rs12.81 Billion |
|
Finwise Bancorp
NASDAQ:FINW
|
USA | $783.94 Million |
|
Gulf Island Fabrication Inc
NASDAQ:GIFI
|
USA | $52.42 Million |
|
SOL-GEL TECHN. IS-10
F:4SG
|
Germany | €7.11 Million |
|
CVW CleanTech Inc
V:CVW
|
Canada | CA$861.47K |
|
GTM Holdings Corp
TW:1437
|
Taiwan | NT$5.43 Billion |
|
Hoegh LNG Partners LP
OL:HLNG
|
Norway | Nkr1.69 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Unicycive Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see UNCY company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Unicycive Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Unicycive Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Unicycive Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $18.94 Million | -21.86% |
| 2024-12-31 | $24.24 Million | +34.65% |
| 2023-12-31 | $18.00 Million | +448.11% |
| 2022-12-31 | $3.28 Million | +45.31% |
| 2021-12-31 | $2.26 Million | -21.39% |
| 2020-12-31 | $2.88 Million | +218.38% |
| 2019-12-31 | $903.00K | -26.88% |
| 2018-12-31 | $1.24 Million | -- |
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester deriv… Read more